Last updated on April 18, 2014 at 17:24 EDT

Latest David L. Lacey Stories

2012-10-25 03:21:27

BREDA, the Netherlands and GHENT, Belgium, October 25, 2012 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey. Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a...

2012-03-15 14:00:00

SAN DIEGO, March 15, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of David L. Lacey, M.D. and Michael Gallatin, Ph.D. to the company's Therapeutic Advisory Board (TAB). Drs. Lacey and Gallatin will join two founding members of AnaptysBio's TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, Ph.D. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) AnaptysBio's TAB is constituted to oversee the company's...